Physician profile
Sean Heffron
NPI 1316106776
$12,002.51
in general payments reported to CMS, 2019-2025
11 companies · $20.41 in 2025
The $20.41 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $56.58 · 2021: $232 · 2022: $11K · 2023: $59.36 · 2025: $20.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11,277.63 | 2022 | |
| Amarin Pharma, INC. | $241.37 | 2019-2022 | |
| Amgen INC. | $226.50 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $61.26 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $55.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.74 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2023 | |
| Lilly USA, LLC | $20.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.78 | 2021 | |
| Pfizer INC. | $15.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Heffron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.